Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins

被引:508
作者
Reynolds, LE
Wyder, L
Lively, JC
Taverna, D
Robinson, SD
Huang, XZ
Sheppard, D
Hynes, O
Hodivala-Dilke, KM [1 ]
机构
[1] St Thomas Hosp, Cell Adhes & Dis Lab, Richard Dimbleby Dept, Imperial Canc Res Fund, London, England
[2] MIT, Ctr Canc Res, Howard Hughes Med Inst, Cambridge, MA 02139 USA
[3] Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA
关键词
D O I
10.1038/nm0102-27
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Inhibition of a alpha (v)beta (3) or alpha (v)beta (5) integrin function has been reported to suppress neovascularization and tumor growth, suggesting that these integrins are critical modulators of angiogenesis. Here we report that mice lacking beta (3) integrins or both beta (3) and beta (5) integrins not only support tumorigenesis, but have enhanced tumor growth as well: Moreover, the tumors in these integrin-deficient mice display enhanced angiogenesis, strongly suggesting that neither beta (3) nor beta (5) integrins are essential for neovascularization. We, also observed that angiogenic responses to hypoxia and vascular endothelial growth factor (VEGF) are augmented significantly in the absence of beta (3) integrins. We found no evidence that the expression or functions of other integrins were altered as a consequence of the beta (3) deficiency, but we did observe elevated levels of VEGF receptor-2 (also called Flk-1) in beta (3)-null endothelial cells. These data indicate that a alpha (v)beta (3) and alpha (v)beta (5) integrins are not essential for vascular development or pathological angiogenesis and highlight the need for further evaluation of the mechanisms of action of alpha (v)-integrin antagonists in anti-angiogenic therapeutics.
引用
收藏
页码:27 / 34
页数:8
相关论文
共 45 条
  • [11] Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
    Carmeliet, P
    Ferreira, V
    Breier, G
    Pollefeyt, S
    Kieckens, L
    Gertsenstein, M
    Fahrig, M
    Vandenhoeck, A
    Harpal, K
    Eberhardt, C
    Declercq, C
    Pawling, J
    Moons, L
    Collen, D
    Risau, W
    Nagy, A
    [J]. NATURE, 1996, 380 (6573) : 435 - 439
  • [12] Angiogenesis in cancer and other diseases
    Carmeliet, P
    Jain, RK
    [J]. NATURE, 2000, 407 (6801) : 249 - 257
  • [13] CHEN YP, 1994, J BIOL CHEM, V269, P18307
  • [14] Trans-dominant inhibition of integrin function
    DiazGonzalez, F
    Forsyth, J
    Steiner, B
    Ginsberg, MH
    [J]. MOLECULAR BIOLOGY OF THE CELL, 1996, 7 (12) : 1939 - 1951
  • [15] DRAKE CJ, 1995, J CELL SCI, V108, P2655
  • [16] The role of αv integrins during angiogenesis:: insights into potential mechanisms of action and clinical development
    Eliceiri, BP
    Cheresh, DA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (09) : 1227 - 1230
  • [17] Clinical applications of angiogenic growth factors and their inhibitors
    Ferrara, N
    Alitalo, K
    [J]. NATURE MEDICINE, 1999, 5 (12) : 1359 - 1364
  • [18] ROLE OF THE FLT-1 RECEPTOR TYROSINE KINASE IN REGULATING THE ASSEMBLY OF VASCULAR ENDOTHELIUM
    FONG, GH
    ROSSANT, J
    GERTSENSTEIN, M
    BREITMAN, ML
    [J]. NATURE, 1995, 376 (6535) : 66 - 70
  • [19] DEFINITION OF 2 ANGIOGENIC PATHWAYS BY DISTINCT ALPHA(V) INTEGRINS
    FRIEDLANDER, M
    BROOKS, PC
    SHAFFER, RW
    KINCAID, CM
    VARNER, JA
    CHERESH, DA
    [J]. SCIENCE, 1995, 270 (5241) : 1500 - 1502
  • [20] Involvement of integrins alpha(v)beta(3) and alpha(v)beta(5) in ocular neovascular diseases
    Friedlander, M
    Theesfeld, CL
    Sugita, M
    Fruttiger, M
    Thomas, MA
    Chang, S
    Cheresh, DA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (18) : 9764 - 9769